Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H5MS
|
|||
| Former ID |
DIB000199
|
|||
| Drug Name |
CT84.66
|
|||
| Synonyms |
T84.66; Anti-CEA IgG1 radioimmunotherapeutic, City of Hope; Anti-carcinoembryonic antigen IgG1 radioimmunotherapeutic, City ofHope
Click to Show/Hide
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 1/2 | [1] | |
| Company |
City of Hope
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carcinoembryonic antigen CEA (CD66e) | Target Info | . | [2] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00645710) Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery. U.S. National Institutes of Health. | |||
| REF 2 | Technology evaluation: cT84.66, City of Hope. Curr Opin Mol Ther. 2004 Feb;6(1):90-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.